Year All20262025202420232022202120202019 Mar 04, 2026 Harmony Biosciences to Participate in Upcoming Investor Conferences Feb 24, 2026 Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion Feb 17, 2026 Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy Feb 10, 2026 Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 Jan 12, 2026 Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation Jan 07, 2026 Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Feb 24, 2026 Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
Feb 17, 2026 Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
Feb 10, 2026 Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Jan 12, 2026 Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation
